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The mupirocin trans-AT polyketide synthase pathway, provides a model system for manipulation 
of antibiotic biosynthesis. Its final phase involves removal of the tertiary hydroxyl group from 
pseudomonic acid B, PA-B, producing the fully active PA-A in a complex series of steps. To further 
clarify requirements for this conversion, we fed extracts containing PA-B to mutants of the producer 
strain singly deficient in each mup gene. This additionally identified mupM and mupN as required plus 
the sequence but not enzymic activity of mupL and ruled out need for other mup genes. A plasmid 
expressing mupLMNOPVCFU + macpE together with a derivative of the producer P. fluorescens strain 
NCIMB10586 lacking the mup cluster allowed conversion of PA-B to PA-A. MupN converts apo-mAcpE 
to holo-form while MupM is a mupirocin-resistant isoleucyl tRNA synthase, preventing self-poisoning. 
Surprisingly, the expression plasmid failed to allow the closely related P. fluorescens strain SBW25 to 
convert PA-B to PA-A.
Polyketide synthases (PKSs) are responsible for the synthesis of a huge diversity of secondary metabolites includ-
ing antibiotics in clinical use, for example erythromycin1–3. Analysis of the genes encoding PKSs has revealed the 
way that this diversity has evolved via the combinatorial possibilities inherent in the backbone assembled by the 
PKS components and the recruitment of additional genes that are able to modify the backbone thus generating a 
range of novel structures4. Thus there is great potential for re-engineering PKS pathways to yield new molecules 
with novel biological activities5,6. In practice it has not been so easy to achieve this ambition. It is thought that a 
lack of structural understanding of these complex machines is what has confounded many attempts and so con-
siderable effort has focused on understanding the way in which these complex structures are assembled7.
PKSs are broadly classified as type I or II depending on whether the individual enzyme activities are encoded 
as parts of multifunctional polypeptides (TI) or as individual polypeptides that assemble into multi-enzyme com-
plexes (TII)4. The mupirocin system8–10 was one of the first discovered trans-acyl transferase (AT) TI PKSs in 
which the AT which loads the malonate extender unit onto Acyl Carrier Proteins (ACPs) of the biosynthetic 
factory is made as a separate polypeptide11–13. The mupirocin system consists of three polyketide synthases, 
MmpA, MmpD, MmpB, which create a 23 carbon backbone, and five auxiliary ACPs (mAcpABCDE) and further 
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enzymes for regulating the gene cluster and tailoring the structure of the polyketide during and post synthesis, 
MupA through to MupZ10 (Fig. S1). Mupirocin has a number of chemical features whose biosynthetic machinery 
is not fully understood and which can potentially be added to a synthetic biology toolbox for the creation of novel 
pathways10.
One such feature is the tetrahydropyran ring that is essential for mupirocin activity, creating the structure that 
occupies the nucleotide binding site of the isoleucyl-tRNA synthetase active site14. MupW and T are necessary for 
tetrahydropyran ring formation but leave an hydroxyl group at C-8 of monic acid, characteristic of pseudomonic 
acid B15–17, as shown in Fig. 1. One of the surprises of our early mutational analysis of mupirocin biosynthesis 
was that PA-B might be an intermediate15,18, since mutants defective in mupO, mupU, mupV and macpE no 
longer produced PA-A but accumulated PA-B instead15, and this was confirmed by showing that mutants of 
genes implicated early in the pathway can convert PA-B to PA-A but that mutants of the later stages cannot17,19. 
Since all these mutants have the same phenotype their gene products were proposed to work together and based 
on predicted functions following BLAST analysis MupU (a predicted acyl-ACP synthase) was proposed to load 
PA-B onto mAcpE where it was oxidised by MupO (a P450 predicted oxidoreductase) before release by MupV, 
one domain of which is a predicted thioesterase. Further analysis of mutants of mupC18, mupF17 and mupP19, 
including double mutants with these PA-B-producer alleles, showed that MupC (a predicted enone reductase), 
MupF (a predicted ketoreductase) and MupP (a predicted dehydratase) act at a later stage. The structure of the 
intermediate Mupirocin P was characterised from a double mutant that cannot create the epoxide ring and this 
made the compound more stable19. Further isolation of other double mutants plus LC-MS and NMR elucidation 
of the structures of isolatable intermediates allowed prediction of the current scheme (Fig. 1). However, because 
this conversion has proven to be surprisingly complex and the current scheme for how this occurs may still not be 
the full story, this study aimed to define the full set of mup genes needed for conversion of PA-B to PA-A.
Results
Screening all mup cluster tailoring genes for PA-B to PA-A conversion. To methodically identify 
all genes of the mup cluster that are required for PA-B to PA-A conversion we screened previously constructed 
mutant strains, each with a defect in one of the 35 mupirocin tailoring genes (Table S1) leading to loss of PA-A. 
For completeness we also included the strains that had previously been shown to accumulate PA-B. Cultures were 
grown as described in Methods with 0.5% (v/v) methanol or 0.5% PA-B extract in methanol, initially in duplicate, 
and supernatants analysed by HPLC. The amount of PA-A and PA-B present in each sample was determined by 
integration of HPLC peak areas. To determine the percentage of conversion of fed PA-B to PA-A, samples were 
first adjusted for their methanol controls, to account for any inherent production of either compound by the 
strains. This screening method proved successful, with a distinct difference in phenotype between converters and 
non-converters for the majority of genes (Fig. 2). Mutants of genes macpE, mupF, mupO, mupP, mupU and mupV 
Figure 1. Proposed pathway for conversion of PA-B to PA-A.
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were confirmed as deficient in conversion as expected based on published data15,18,19 and the cognate enzymes 
already appear in the current model while mutants of genes with characterised functions earlier in the pathway, 
such as mmpA or mupW and mupT, were capable of conversion as expected.
Mutants with defects in three further genes were consistently deficient in conversion: ΔmupM, ΔmupN and 
ΔmupR, although there may be a tiny amount of conversion in the mupN mutant. MupM is an isoleucyl tRNA 
synthetase that provides high level resistance to mupirocin; MupN is a phosphopantetheinyl transferase (PPTase); 
and MupR is the transcriptional activator required for mupirocin gene expression20. The lack of conversion by 
the ΔmupM strain prompted further investigation and we established that such strains stopped growing at lower 
density than WT, but remain viable, possibly the result of the stringent response due “starvation” for isoleucine. 
Thus the requirement for mupM is most likely to prevent this self-inhibition. The requirement for MupN in the 
Figure 2. Results of HPLC screening of mup deletion mutants for PA-B to PA-A conversion. Most data are 
based on duplicate cultures (n = no. of replicates) except where results were variable, when larger numbers of 
replicates were performed. Error bars show the extreme values. For ΔmupL, values were either essentially zero 
or approximately 40%. Note that the tiny PA-A peak in the ΔmupN mutant is also present in the in-put PA-B 
profile.
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conversion indicates for the first time that the standard PPTase of P. fluorescens cannot substitute for MupN and 
convert mAcpE to the holoenzyme, although the tiny amount of conversion observed could be due to very weak 
conversion of traces of mAcpE to holo-form. The ability of the ΔmupI mutant to convert was initially surprising 
since MupI, which produces homoserine lactone, is essential for activating all stages of mupirocin production. 
However, the presence of significant levels of homoserine lactone in the crude extract of PA-B was confirmed by 
showing that it could activate the xylE reporter gene integrated into mupA in a ΔmupI xylE::mupA strain which 
is defective in homoserine lactone production (Fig. S2)21.
Two further mutants demonstrated an intermediate phenotype, ΔmupC and ΔmupL. MupC is a predicted 
NADH:flavin oxidoreductase and possibly a dienoyl reductase while MupL is a putative alpha/beta hydrolase. 
The partial conversion of PA-B to PA-A by the mupC mutant agrees with the previous observation that such a 
mutant produces a lower titre of PA-A than WT, as well as intermediate metabolites mupirocin C1 and C2 (Fig. 1) 
which differ by the formation of a cyclic ether ring formed by the C7-OH attacking the C10-C11 epoxide ring17. It 
was deduced that the tautomerisation to produce mupirocin F1 can occur spontaneously but that MupC favours 
mupirocin F1 formation17. The ability of the ΔmupL mutant cultures to convert PA-B to PA-A was inconsistent, 
about half of all cultures (n = 16) converting and the others failing to. This variability was not due to a permanent 
change in the strain and was observed for all three independent ΔmupL mutant strains with the same, original 
in-frame deletion. This indicated that conversion could take place in the absence of a functional MupL protein 
and suggested that, since mupL is immediately upstream of mupM, the mupL deletion may remove sequences 
important for normal mupM transcription, possibly resulting in some cultures expressing mupM and others not 
doing so, and thus self-inhibiting. We concluded that mupL should be included upstream of mupM in the set of 
genes chosen for PA-B to PA-A conversion but that its requirement should be investigated more thoroughly at 
that stage.
Both domains of MupV are required for PA-B to PA-A conversion. All the genes identified in the 
screen for PA-B to PA-A conversion described above are predicted to encode a single biochemical function apart 
from mupV. MupV was originally predicted to be an oxidoreductase9, but re-analysis of the amino acid sequence 
predicted two domains: the previously identified domain 1 predicted as a short chain dehydrogenase/reductase 
(SDR) (Blast E-value 1.46E–91) and a second domain predicted as an alpha-beta hydrolase or thioesterase (TE), 
(Blast E-value 9.12E–4). The hypothesis that MupV acts as a thioesterase19 provides a mechanism for release of 
the polyketide from mAcpE but does not explain the presence of two domains. Therefore, point mutations to con-
served residues were designed to test whether the functions of both are required for conversion of PA-B to PA-A. 
For domain 1 (SDR) the Tyr176 in the active site NAD-binding Rossman fold YxxxK motif 22 was changed to 
Phe, minimising the chance of structural changes to the enzyme. There are no predicted well-characterised active 
site motifs in Domain 2 (TE) but alignment of 55 related sequences revealed a strongly conserved His which was 
mutated to Ala (Fig. S3). Overlap extension PCR was used to generate mutagenic segments that were inserted into 
the suicide vector pJC70 and the mutations transferred into the chromosome of NCIMB10586 using standard 
procedures. A second mutation in domain 2, V581A, occurred by chance in the mutagenic suicide plasmid and 
all clones identified with H631A also had the V581A mutation. Because some clones had the V581A mutation 
on its own we decided to see whether this single mutation alone had any effect on MupV activity before starting 
again to make the mutagenic suicide plasmid. The three mupV mutant strains were assayed for active mupirocin 
production with Bacillus subtilis as the indicator. Both the Y167F and H631A (with V581A) mutations decreased 
the zones of inhibition compared with WT, whereas the V581A mutation showed no effect (Fig. S4), consistent 
with an I-Tasser 3D model of MupV which predicts that this residue is situated well away from the active site. 
HPLC analysis (Fig. S5) followed by LC-MS and 1H-NMR (Fig. S6) demonstrated that both domains are required 
for conversion of PA-B to PA-A. This suggests that either both domains are involved in the proposed release from 
MacpE, or that MupV has an additional role in PA-B to PA-A conversion.
Conversion of PA-B to PA-A achieved by selected mup genes in an expression plasmid. To 
check whether the genes identified by the screening described above are sufficient for PA-B to PA-A conversion, 
we constructed a broad host range expression plasmid with all these genes spliced together as an operon down-
stream of the tac promoter (pJC133; Fig. 3A and Table 1). Plasmid pJC133 was constructed carrying genes mupO, 
P, macpE, mupU, V, C, F, L, M and N. To determine the need for the mupL sequence, a variant without mupL was 
constructed, pJC132. The mupL, M, N block was added at the downstream end because if the natural complete 
gene sequence from mupL to mupP had been included as the start of the operon we worried that there could be a 
problem due to an inverted repeat downstream of mupN that might be a transcriptional terminator.
The functionality of each gene in each plasmid was checked by complementation and plate bioassay for anti-
biotic production performed with and without IPTG (0.5 mM; Fig. 3B). The ability to complement PA-A produc-
tion in mupL, mupM and mupN in-frame deletion mutants was also checked by HPLC (Fig. S7). Without IPTG 
pJC133 could complement all three mutants, while pJC132 could only complement the mupN mutant despite 
the presence of what should be the complete mupM sequence including its ribosome binding site, suggesting a 
defect in expression of mupM. With IPTG a mupM mutant could also be at least partially complemented. This 
suggests that the mupL sequence is necessary to achieve sufficient expression of mupM for complementation but 
that mupN is either not dependent in the same way (perhaps there is an additional promoter within mupM for 
mupN) or that lower levels of mupN expression are sufficient for complementation. An inverted repeat down-
stream of mupM in the gap before mupN could potentially influence the mupM mRNA separately from the mupN 
mRNA but there is no obvious promoter-like sequence that could serve mupN but not mupM and detailed anal-
ysis is beyond the scope of this paper. A point mutation (H256A) that should inactivate the enzymic activity of 
MupL was introduced into pJC133 (giving pJC134) to test the prediction that this region is only needed to allow 
mupM expression. This mutation destroyed the ability to complement the mupL deletion mutant but the mupM 
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functionality was maintained (Fig. 3B) in line with our prediction that mupL may contain a promoter for mupM. 
The 3′ end of the mupL gene contains a number of possible promoter-like sequences and inverted repeats that 
may be relevant but experimental evidence to distinguish the various explanations is not yet available. However, 
none of these potential promoters contains the sequences that we predict are the mupR binding site, suggesting 
that basal mupM expression is constitutive rather than quorum-regulated. Higher level of mupM expression than 
for the other mup genes may be necessary to ensure that the bacterium can continue to grow once mupirocin 
production is initiated.
Finally, pJC132, pJC133 and pJC134 were all introduced into a NCIMB10586 deletion derivative that had lost 
all of the mup cluster biosynthetic genes (as opposed to regulatory genes) from the first gene, mupZ, to mupW, 
the last gene before the mupRXI regulatory cluster. The ability to convert PA-B to PA-A was tested in the presence 
(0.5 mM) and absence of IPTG. The presence of both pJC133 and pJC134 but not pJC132 allowed conversion in 
the absence of IPTG but none of the plasmids were able to do that in the presence of IPTG (Fig. 4) indicating that 
low level expression from the leaky tac promoter is sufficient for the majority of the genes is sufficient for func-
tion. These plasmids were also introduced into the closely related strain P. fluorescens SBW2523 but this host was 
found not to allow any of the plasmids to catalyse conversion of PA-B to PA-A.
Figure 3. Expression plasmid with all mup genes needed for conversion of PA-B to PA-A. (A) Plasmid map. 
(B) Functional bioassays for each gene in the constructed plasmids (see Table 1) using B. subtilis; the best 
performing IPTG induction condition is shown, which was 0.5 mM IPTG for ΔmupM [pJC132] and ΔmupN 
[pJC132] and 0 mM IPTG for all other samples; n = 3, error bars are standard deviation. For ΔmupN the strain 
with pJH10 gave so little activity the column is not visible.
Plasmid Mupirocin genes carried PA-B to PA-A?
pJH10 none ✗
pJC132 mupO, P, macpE, mupU, V, C, F, M, N ✗
pJC133 mupO, P, macpE, mupU, V, C, F, L, M, N ✓
pJC134 mupO, P, macpE, mupU, V, C, F, L
−, M, N 
(mupL inactivated by point mutation) ✓
Table 1. Summary of expression plasmids in this study.
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Discussion
The work described in this paper has systematically demonstrated for the first time which genes from the mup 
cluster are necessary for PA-B to PA-A conversion during mupirocin biosynthesis and which genes are not. 
Gratifyingly, it turns out that we had already identified all the enzymes directly involved in the PA-B to PA-A 
conversion encoded by genes of the mup cluster, so the proposed pathway in Fig. 1 still functions as a working 
model. This does not mean that no questions remain.
Our previous studies with mupN, which encodes an Sfp-like PPTase24, had shown only that it is needed to 
activate at least some of the ACPs encoded in the mup cluster18,25. Shields et al.25 showed that, at least in E. coli, 
some mup ACPs are not totally dependent on MupN: when the macpA gene was expressed in E. coli in the absence 
and presence of cloned mupN, mass-spectrometry detected mAcpA as holo-ACP even without MupN present. In 
the Shields et al.25 study, mAcpE had proven impossible to produce in soluble form and so the requirements for 
its conversion to holoenzyme could not be determined. In the current study the only ACP required for the PA-B 
to PA-A conversion is mAcpE and so the simplest explanation for the additional requirement for mupN is that it 
is essential for conversion of mAcpE to its active holo- (phosphopantetheinylated) form. Understanding of the 
code that determines the specificity of different PPTases on ACPs is not yet complete enough to spell out the basis 
of this requirement24.
Our bioinformatic and mutational analysis shows that MupV (662 aa) consists of two distinct domains which 
are both necessary for the transformation. Domain 1 (approximately amino acids 1–320) is predicted to belong to 
the short-chain dehydrogenase/reductase (SDR) superfamily while domain 2 is predicted to be an α/β hydrolase. 
Although there is not yet any direct evidence for the role of MupV, the absence of MupV and mAcpE homo-
logues encoded by the biosynthetic cluster for the related polyketide antibiotic thiomarinol10 and an extra in 
cis module in TmpB26 suggest that removal of the 8-OH may occur on the ACP of this second TmpB module so 
that mAcpE and MupV are not needed. On this model the domain 2 seems most likely to be a thioesterase that 
is needed to release products from mAcpE27. The potential role of domain 1 is more enigmatic but since the SDR 
family includes enzymes that do neither oxidation nor reduction22, a possibility is that it works with MupU in 
loading mAcpE. Thus, as proposed for TmlU in thiomarinol biosynthesis28, rather than transferring PA-B direct 
to mAcpE, MupU may activate PA-B by transfer to coenzyme A and MupV domain 1 may transfer it to mAcpE. 
Such a dual role for a single bi-domain protein in loading/off-loading ACPs might make a lot of sense in other 
contexts and interestingly a Blast search shows that there are numerous distantly related proteins that also have 
both of these functions paired in a single dual-domain protein. Another possibility is that mupirocin P arises 
from the dual action of MupO and MupV rather than just MupO. So far this has proven intractable as mupV 
knockouts simply yield PA-B (Fig. S6) and shed no light on the “true” MupO product.
It is also intriguing that pJC133 encoding the complete set of genes could not convert PA-B to PA-A in P. 
fluorescens SBW25 and this would be consistent with the identification of transposon insertion mutants of 
NCIMB10586 defective in mupirocin production and mapping away from the cluster of insertions that defined 
the region encoding the mup cluster we have studied for many years29. The problem with P. fluorescens SBW25 
could be simply that PA-B cannot enter or PA-A cannot exit efficiently. Alternatively, one or more components 
encoded elsewhere on the genome in NCIMB10586 may be necessary for the conversion. The finding that MupM 
is essential for the conversion and that the mupL sequence is important in giving a consistent ability to convert 
PA-B to PA-A, can underpin future work to define additional components if none of the mutants described by 
Whatling et al.29 identify the locus required. A new transposon insertion library could be screened for strains that 
are not adversely affected by feeding PA-B: mutants that are not able to make the inhibitory PA-A will be enriched. 
Figure 4. HPLC analysis of extracts from cultures grown without added IPTG showing multi-gene expression 
plasmids pJC133 and pJC132 encode all functions necessary to restore conversion of exogenous PA-B to PA-A 
in 10586 Δmup-cluster. No conversion was observed with plasmid pJC132, which lacks the mupL gene.
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Thus, the analysis we have described lays the basis for working out, not just what the Mup proteins involved are 
doing but how the pathway fits into the broader context of its bacterial host.
Methods
Bacterial strains, plasmids and growth conditions. Bacterial strains are listed in Supplementary 
Table S1. Plasmids used and constructed in this study are listed in Supplementary Table S2. Oligonucleotides 
are listed in Supplementary Table S3. Routine methods were as described previously30. Bacteria were routinely 
cultured at either 37 °C (E. coli and B. subtilis) or 30 °C (P. fluorescens) in lysogeny broth (LB) with shaking at 
200 rpm or on Lagar (LB + 1.5% w/v agar). P. fluorescens was grown on standard M9 minimal medium agar with 
glucose to counter-select against E. coli. Prior to assay of secondary metabolite production by HPLC, P. fluorescens 
was cultured in Secondary Stage Medium (SSM). Antibiotics used were ampicillin (100 µg ml−1) and kanamycin 
(50 µg ml−1).
To prepare SSM, a mixture of 25 g soya flour, 2.5 g spray dried corn liquor, 5 g (NH4)2SO4, 0.5 g MgSO4.7H2O, 
1 g Na2HPO4, 1.5 g K2HPO4, 1 g KCl, and 6.25 g CaCO3 was generated. The pH of the mixture was adjusted to 7.5, 
made up to 1 L dH2O and autoclaved. Before use 40% (w/v) glucose was added to the SSM to give a final concen-
tration of 4%.
Conjugative transfer of plasmids to P. fluorescens. Plasmids carrying oriT were first introduced into 
E. coli S17-131 by transformation, which has the RP4 tra regions integrated into the chromosome, enabling conju-
gative transfer of plasmids with oriT. Overnight (16 hour) cultures of donor S17-1 carrying the relevant plasmid 
were grown in LB with antibiotic selection for the plasmid. Simultaneously, 16 hr cultures of the recipient P. 
fluorescens strains were grown in LB. To allow conjugation to occur, 10 µl of both donor and recipient cultures 
were spotted on top of each other on L-agar and then incubated at 30 °C for 12–20 hours. The mixed cultures 
were streaked to single colonies on L-agar with ampicillin to select for P. fluorescens, and the antibiotic selective 
for the plasmid. Transconjugants were again streaked onto selective plates to minimise the risk of E. coli donor 
contamination.
Mutagenesis of P. fluorescens. Suicide plasmids were mobilised to P. fluorescens by conjugation from 
E. coli S17-1. Transconjugants were selected with ampicillin or on M9 minimal medium (for P. fluorescens) and 
kanamycin (for pAKE604- or pJC70-derived plasmids). These plasmids have the pMB1 replicon, which does not 
function in P. fluorescens. Therefore, kanamycin selects for plasmids that have integrated into the Pseudomonas 
chromosome by homologous recombination. Transconjugant colonies were re-streaked to ensure they were free 
of the donor E. coli strain and then grown in LB without selection for 16 hours to allow a second recombination 
event to occur. The vectors include sacB, which encodes levansucrase from Bacillus subtilis, which confers a lethal 
periplasmic sucrose polymerisation in Gram negative bacteria32. Serial dilutions of these cultures were plated 
onto L-agar with 5% (w/v) sucrose, which selects for bacteria that have lost sacB. Sucrose resistant colonies were 
then patched onto L-agar with and without kanamycin, to check for plasmid loss. Since the integration and exci-
sion events have an equal chance of occurring in either homology arm flanking the mutation, about 50% of the 
excisants should contain the mutation. Mutant strains were detected by PCR, restriction digest and sequencing. 
Strains with multiple genes knocked out were either made by a single deletion if the genes were adjacent (eg 
ΔmupQ, mupS, macpD, mmpF) or by sequencial knockouts (eg ΔmupW, ΔmupT).
Extraction of PA-B. Ethyl acetate extraction was used to concentrate PA-B for use in the feeding experi-
ments. Plasmid pJH2 (IncQ vector with mupR under tac promoter control) was mobilised to the PA-B-producing 
strain NCIMB10586 ΔmupU, as expression of transcription factor MupR increases secondary metabolite yield18. 
Seed cultures were grown overnight at 30 °C in LB. SSM cultures (200 ml) in 2 L conical flasks, were inoculated 
with 2 ml of saturated seed culture, and incubated at 22 °C for 40–44 hours.
Cultures were aliquoted into 50 ml Falcon conical centrifuge tubes and centrifuged at 3000 × g for 10 minutes 
at room temperature. The supernatants were collected and pH adjusted to 4.5, before being split into aliquots in 
50 ml Falcon tubes, approximately half full (25 ml). To each tube was added approximately 25 ml ethyl acetate 
(EtOAc), mixed thoroughly by inversion and vortexing approximately ten times over half an hour. Where emul-
sions were formed, these were resolved to layers by centrifugation (3000 × g, 5 minutes). The clear top layer was 
collected using a glass pipette. Each tube was refilled with EtOAc, and the process repeated, again collecting the 
top layer. The collected solvent was evaporated on a rotary evaporator until <500 µl oily yellow liquid remained. 
Methanol (2 to 4 ml) was added and any precipitated solids dissolved by pipetting. The purity and concentration 
of the extract was determined by HPLC analysis.
High performance liquid chromatography. To prepare samples for HPLC analysis, P. fluorescens 5 ml 
LB seed cultures, with suitable antibiotics, were inoculated in triplicate from single colonies on solid medium and 
incubated for 16 hours at 30 °C. Seed cultures (200 µl) were used to inoculate 5 ml SSM in 50 ml conical flasks, 
which were incubated at 22 °C 200 rpm for 44 hours. Samples were centrifuged at 13,000 g and supernatants col-
lected. The supernatants were filtered through 0.2 µm millipore filters prior to injection.
HPLC analysis was performed on a Gilson system using a reverse phase C18 column. Mobile phase was a 
water:acetonitrile gradient, starting from 95:5 (t = 0 minutes) to 30:70 (t = 30 minutes). Both the HPLC grade 
water and acetronitrile were made up with 0.01% formic acid. Compounds were detected by UV absorption at 
233 nm.
PA-B feeding experiments. To screen bacterial strains for their ability to convert PA-B to PA-A SSM 
cultures (5 ml) were supplemented with PA-B extract (at 0.5 to 1.0% (v/v) to give a concentration of approxi-
mately 150 µM) or an equivalent amount of methanol as a negative control, and incubated at 22 °C 200 rpm for 
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44 hours before HPLC analysis. Where necessary IPTG was also added at 0.5 mM to induce expression from the 
tac promoter.
Plate bioassay. Plate bioassays were used to determine the antibiotic activity of test P. fluorescens strains 
against the mupirocin-sensitive strain B. subtilis 1604. Cultures of P. fluorescens were grown for 16 hours with suit-
able antibiotics in LB; 10 µl of these were spotted onto 20 ml measured L-agar plates, and incubated for 16 hours at 
20 °C. B. subtilis overnight culture (8 ml) was mixed with 1 ml 5% triphenyl tetrazolium chloride (TTC) in 200 ml 
L-agar. Each plate was overlaid with 15 ml of the B. subtilis-containing mixture. Plates were incubated for 16 hours 
at 37 °C, and the diameters of the zones of inhibition were measured.
Chromogenic xylE reporter assay. NCIMB10586 ΔmupI mupA::xylE has the reporter gene xylE inserted 
downstream of the putative mupA promoter21 and is defective in the cognate homoserine lactone (HSL) quorum 
sensing signal molecule. The level of xylE expression was used to detect exogenous HSL. To perform the assays, 
overnight LB cultures of the reporter and relevant test strains were streaked onto SSM agar plates, which were 
incubated for 22 hours at 20 °C. Plates were then mist-sprayed with 1% (w/v) catechol in SDW, and the colour 
change was observed after 5 minutes. Colourless catechol is converted to yellow 2-hydroxymuconic semialdehyde, 
catalysed by XylE33, allowing for detection of transcription from the mupA promoter.
Quantification and statistical analysis. HPLC data were exported from the Gilson Unipoint software 
that operates the machinery to OriginPro2016. Peak areas were calculated in OriginPro2016 using the inbuilt 
Peak Analyzer tool with the baseline mode set to asymmetric least squares smoothing.
To determine the percentage of conversion of fed PA-B to PA-A in the Fig. 2 dataset, samples were first 
adjusted for their methanol controls, to account for any inherent production of either compound by the strains. 
Percentage conversion was calculated as the amount of PA-A produced divided by the total pseudomonic acids 
produced (PA-A and PA-B).
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